North America & Europe Epilepsy Market
完整報告名稱與涵蓋範圍
North America & Europe Epilepsy Market Research Report Information By Condition (Generalized Epilepsy And Focal Epilepsy), By diagnosis & treatment, By End User (hospitals & clinics, diagnostic centers, and others), By Region (US, Canada, Europe) Forecast to 2032
報告摘要
North America & Europe Epilepsy Market Research Report Information Forecast to 2032
By Condition (Generalized Epilepsy And Focal Epilepsy), By diagnosis & treatment, By End User (hospitals & clinics, diagnostic centers, and others), By Region (US, Canada, Europe)
Market Overview
It is expected that the North America and Europe Epilepsy Market will experience a robust market growth rate of 8.18% during the review period. Epilepsy is a chronic neurological condition that results in recurrent seizures and effects the brain. Seizures are episodes of uncontrolled electrical activity in the brain that can result in alterations in sensation, movement, consciousness, and behavior.
The North American and European epilepsy market is being driven by the growing awareness and understanding of epilepsy, as well as the increasing incidences of epilepsy in these regions. Nevertheless, the epilepsy market in North America and Europe is anticipated to be constrained by the adverse effects of antiepileptic drugs. However, it is anticipated that the market will generate lucrative opportunities as a result of the growing number of clinical trials for epilepsy diagnosis products and the increased investment in epilepsy diagnosis and treatment research.
Market Segmentation
The epilepsy market in North America and Europe has been segmented into generalized epilepsy and focal epilepsy, as determined by the condition.
The North American and European epilepsy market has been segmented into diagnosis and treatment.
The market has been segmented into hospitals & clinics, diagnostic centers, and others based on the end consumer.
In 2022, the North American epilepsy market was valued at USD 6,888.72 million and is anticipated to register a compound annual growth rate (CAGR) of 7.88% throughout the forecast period. The United States and Canada are the two additional segments of North America.
Major Players
Sun Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, Novartis AG, GlaxoSmithKline, Boston Scientific Corporation, Abbott, Cipla ltd., UCB S. A, H. Lundbeck A/S, and Eisai Co., Ltd. are key market participants.
授權報價
| Single User Price | $2,950 USD |
| Multi User Licence (up to 10 users) | $3,950 USD |
| Enterprisewide Price (Global Site License) | $5,250 USD |
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 17
2 MARKET INTRODUCTION 19
2.1 DEFINITION 19
2.2 SCOPE OF THE STUDY 19
2.3 RESEARCH OBJECTIVE 19
2.4 MARKET STRUCTURE 20
3 RESEARCH METHODOLOGY 21
3.1 OVERVIEW 21
3.2 DATA FLOW 23
3.2.1 DATA MINING PROCESS 23
3.3 PURCHASED DATABASE: 24
3.4 SECONDARY SOURCES: 25
3.4.1 SECONDARY RESEARCH DATA FLOW: 26
3.5 PRIMARY RESEARCH: 27
3.5.1 PRIMARY RESEARCH DATA FLOW: 28
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 29
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 30
3.6.1 REVENUE ANALYSIS APPROACH 30
3.7 DATA FORECASTING 31
3.7.1 DATA FORECASTING TYPE 31
3.8 DATA MODELING 32
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 32
3.8.2 DATA MODELING: 33
3.9 TEAMS AND ANALYST CONTRIBUTION 35
4 MARKET DYNAMICS 37
4.1 INTRODUCTION 37
4.2 DRIVERS 38
4.2.1 INCREASING INCIDENCES OF EPILEPSY IN NORTH AMERICA AND EUROPE REGION 38
4.2.2 RISING AWARENESS AND UNDERSTANDING OF EPILEPSY 38
4.3 RESTRAINTS 40
4.3.1 SIDE EFFECTS ASSOCIATED WITH ANTIEPILEPTIC DRUGS 40
4.4 OPPORTUNITY 41
4.4.1 INCREASING INVESTMENT FOR EPILEPSY DIAGNOSIS & TREATMENT RESEARCH 41
4.4.2 GROWING CLINICAL TRIALS FOR EPILEPSY TREATMENT PRODUCTS 41
5 MARKET FACTOR ANALYSIS 42
5.1 PORTER'S FIVE FORCES MODEL 42
5.1.1 THREAT OF NEW ENTRANTS 42
5.1.2 BARGAINING POWER OF SUPPLIERS 43
5.1.3 THREAT OF SUBSTITUTES 43
5.1.4 BARGAINING POWER OF BUYERS 43
5.1.5 INTENSITY OF RIVALRY 43
5.2 IMPACT OF COVID-19 ON THE NORTH AMERICA AND EUROPE EPILEPSY MARKET 44
5.3 R&D INVESTMENT BY MAJOR PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES ON EPILEPSY 44
5.4 LIST OF FAILED CLINICAL TRIALS FOR EPILEPSY DRUG 45
5.5 CLINICAL TRIAL LANDSCAPE FOR EPILEPSY DRUGS AND DEVICES 46
5.6 CURRENT TRENDS ON SEEG PROCEDURES 47
5.7 QUALITATIVE OVERVIEW ON EPILEPSY TREATMENT MANAGEMENT OTHER THAN DRUGS AND SURGERY 48
6 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY CONDITION 50
6.1 OVERVIEW 50
6.2 GENERALIZED EPILEPSY 52
6.3 FOCAL EPILEPSY 52
7 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT 53
7.1 OVERVIEW 53
7.2 DIAGNOSIS 55
7.2.1 BLOOD TESTS 56
7.2.2 ELECTROENCEPHALOGRAM (EEG) IMAGING TEST 56
7.2.3 IMAGING SCAN 56
7.2.3.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN 57
7.2.3.2 COMPUTERIZED TOMOGRAPHY (CT) SCAN 57
7.2.3.3 OTHERS 58
7.3 TREATMENT 58
7.3.1 DRUG CLASS 59
7.3.1.1 FIRST GENERATION ANTI-EPILEPTIC DRUGS 59
7.3.1.2 SECOND GENERATION ANTI-EPILEPTIC DRUGS 60
7.3.1.3 THIRD GENERATION ANTI-EPILEPTIC DRUGS 60
7.3.2 SURGERY 60
7.3.2.1 FOCAL RESECTION 61
7.3.2.2 LESIONECTOMY 61
7.3.2.3 CORPUS CALLOSOTOMY 62
7.3.2.4 OTHERS 62
7.3.3 THERAPIES 62
7.3.3.1 VAGUS NERVE STIMULATION 63
7.3.3.2 DEEP BRAIN STIMULATION 63
7.3.3.3 RESPONSIVE NEUROSTIMULATION 64
7.3.3.4 THERMOCOAGULATION 64
8 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY END USER 65
8.1 OVERVIEW 65
8.2 HOSPITALS AND CLINICS 67
8.3 DIAGNOSTIC CENTERS 67
8.4 OTHERS 68
9 NORTH AMERICA & EUROPE EPILEPSY MARKET, BY REGION 69
9.1 NORTH AMERICA 69
9.1.1 US 74
9.1.2 CANADA 77
9.2 EUROPE 80
9.2.1 GERMANY 84
9.2.2 FRANCE 87
9.2.3 UK 90
9.2.4 ITALY 93
9.2.5 SPAIN 96
9.2.6 REST OF EUROPE 99
10 COMPETITIVE LANDSCAPE 104
10.1 INTRODUCTION 104
10.2 MARKET SHARE ANALYSIS, 2022 104
10.3 COMPETITOR DASHBOARD 105
10.4 PUBLIC PLAYERS STOCK SUMMARY 106
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 106
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 107
10.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL 107
10.6.2 ACQUISITION 107
11 COMPANY PROFILES 108
11.1 JOHNSON & JOHNSON SERVICES, INC. 108
11.1.1 COMPANY OVERVIEW 108
11.1.2 FINANCIAL OVERVIEW 109
11.1.3 PRODUCTS OFFERED 109
11.1.4 KEY DEVELOPMENTS 109
11.1.5 SWOT ANALYSIS 110
11.1.6 KEY STRATEGY 110
11.2 BOSTON SCIENTIFIC CORPORATION 111
11.2.1 COMPANY OVERVIEW 111
11.2.2 FINANCIAL OVERVIEW 112
11.2.3 PRODUCTS OFFERED 112
11.2.4 KEY DEVELOPMENTS 113
11.2.5 SWOT ANALYSIS 113
11.2.6 KEY STRATEGIES 114
11.3 ABBOTT 115
11.3.1 COMPANY OVERVIEW 115
11.3.2 FINANCIAL OVERVIEW 116
11.3.3 PRODUCTS OFFERED 116
11.3.4 KEY DEVELOPMENTS 116
11.3.5 SWOT ANALYSIS 117
11.3.6 KEY STRATEGIES 117
11.4 CIPLA LTD 118
11.4.1 COMPANY OVERVIEW 118
11.4.2 FINANCIAL OVERVIEW 119
11.4.3 PRODUCTS OFFERED 119
11.4.4 KEY DEVELOPMENTS 119
11.4.5 SWOT ANALYSIS 120
11.4.6 KEY STRATEGIES 120
11.5 UCB S.A 121
11.5.1 COMPANY OVERVIEW 121
11.5.2 FINANCIAL OVERVIEW 122
11.5.3 PRODUCTS OFFERED 122
11.5.4 KEY DEVELOPMENTS 123
11.5.5 KEY STRATEGIES 123
11.6 H. LUNDBECK A/S 124
11.6.1 COMPANY OVERVIEW 124
11.6.2 FINANCIAL OVERVIEW 125
11.6.3 PRODUCTS OFFERED 125
11.6.4 KEY DEVELOPMENTS 125
11.6.5 KEY STRATEGIES 126
11.7 EISAI CO., LTD 127
11.7.1 COMPANY OVERVIEW 127
11.7.2 FINANCIAL OVERVIEW 128
11.7.3 PRODUCTS OFFERED 128
11.7.4 KEY DEVELOPMENTS 128
11.7.5 KEY STRATEGIES 129
11.8 NOVARTIS AG 130
11.8.1 COMPANY OVERVIEW 130
11.8.2 FINANCIAL OVERVIEW 131
11.8.3 PRODUCTS OFFERED 131
11.8.4 KEY DEVELOPMENTS 132
11.8.5 SWOT ANALYSIS 132
11.8.6 KEY STRATEGIES 132
11.9 GLAXOSMITHKLINE PLC 133
11.9.1 COMPANY OVERVIEW 133
11.9.2 FINANCIAL OVERVIEW 134
11.9.3 PRODUCTS OFFERED 134
11.9.4 KEY DEVELOPMENTS 135
11.9.5 KEY STRATEGIES 135
11.10 SUN PHARMACEUTICAL INDUSTRIES LIMITED 136
11.10.1 COMPANY OVERVIEW 136
11.10.2 FINANCIAL OVERVIEW 137
11.10.3 PRODUCTS OFFERED 137
11.10.4 KEY DEVELOPMENTS 138
11.10.5 KEY STRATEGIES 138
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 33
TABLE 2 R&D INVESTMENT BY MAJOR PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES ON EPILEPSY 45
TABLE 3 LIST OF FAILED CLINICAL TRIALS FOR EPILEPSY DRUG 45
TABLE 4 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 51
TABLE 5 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR GENERALIZED EPILEPSY, BY REGION, 2019–2032 (USD MILLION) 52
TABLE 6 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR FOCAL EPILEPSY, BY REGION, 2019–2032 (USD MILLION) 52
TABLE 7 NORTH AMERICA AND EUROPE EPILEPSY MARKET, DIAGNOSIS & TREATMENT SEGMENT ATTRACTIVENESS, 2022-2032 (USD MILLION) 53
TABLE 8 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 54
TABLE 9 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DIAGNOSIS, BY REGION, 2019–2032 (USD MILLION) 55
TABLE 10 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 55
TABLE 11 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR BLOOD TESTS, BY REGION, 2019–2032 (USD MILLION) 56
TABLE 12 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR ELECTROENCEPHALOGRAM (EEG) IMAGING TEST, BY REGION, 2019–2032 (USD MILLION) 56
TABLE 13 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR IMAGING SCAN, BY REGION, 2019–2032 (USD MILLION) 56
TABLE 14 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (USD MILLION) 57
TABLE 15 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR MAGNETIC RESONANCE IMAGING (MRI) SCAN, BY REGION, 2019–2032 (USD MILLION) 57
TABLE 16 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR COMPUTERIZED TOMOGRAPHY (CT) SCAN, BY REGION, 2019–2032 (USD MILLION) 57
TABLE 17 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 58
TABLE 18 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR TREATMENT, BY REGION, 2019–2032 (USD MILLION) 58
TABLE 19 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 58
TABLE 20 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DRUG CLASS, BY REGION, 2019–2032 (USD MILLION) 59
TABLE 21 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 59
TABLE 22 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR FIRST GENERATION ANTI-EPILEPTIC DRUGS, BY REGION, 2019–2032 (USD MILLION) 59
TABLE 23 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR SECOND GENERATION ANTI-EPILEPTIC DRUGS, BY REGION, 2019–2032 (USD MILLION) 60
TABLE 24 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR THIRD GENERATION ANTI-EPILEPTIC DRUGS, BY REGION, 2019–2032 (USD MILLION) 60
TABLE 25 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR SURGERY, BY REGION, 2019–2032 (USD MILLION) 60
TABLE 26 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 61
TABLE 27 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR FOCAL RESECTION, BY REGION, 2019–2032 (USD MILLION) 61
TABLE 28 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR LESIONECTOMY, BY REGION, 2019–2032 (USD MILLION) 61
TABLE 29 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR CORPUS CALLOSOTOMY, BY REGION, 2019–2032 (USD MILLION) 62
TABLE 30 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 62
TABLE 31 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR THERAPIES, BY REGION, 2019–2032 (USD MILLION) 62
TABLE 32 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 63
TABLE 33 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR VAGUS NERVE STIMULATION, BY REGION, 2019–2032 (USD MILLION) 63
TABLE 34 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DEEP BRAIN STIMULATION, BY REGION, 2019–2032 (USD MILLION) 63
TABLE 35 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR RESPONSIVE NEUROSTIMULATION, BY REGION, 2019–2032 (USD MILLION) 64
TABLE 36 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR THERMOCOAGULATION, BY REGION, 2019–2032 (USD MILLION) 64
TABLE 37 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 66
TABLE 38 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR HOSPITALS AND CLINICS, BY REGION, 2019–2032 (USD MILLION) 67
TABLE 39 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2019–2032 (USD MILLION) 67
TABLE 40 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 68
TABLE 41 NORTH AMERICA: EPILEPSY MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 70
TABLE 42 NORTH AMERICA: EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 71
TABLE 43 NORTH AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 71
TABLE 44 NORTH AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 71
TABLE 45 NORTH AMERICA: EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (USD MILLION) 72
TABLE 46 NORTH AMERICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 72
TABLE 47 NORTH AMERICA: EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 72
TABLE 48 NORTH AMERICA: EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 73
TABLE 49 NORTH AMERICA: EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 73
TABLE 50 NORTH AMERICA: EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 73
TABLE 51 US: EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 74
TABLE 52 US: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 74
TABLE 53 US: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 74
TABLE 54 US: EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (USD MILLION) 75
TABLE 55 US: EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 75
TABLE 56 US: EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 75
TABLE 57 US: EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 76
TABLE 58 US: EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 76
TABLE 59 US: EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 76
TABLE 60 CANADA: EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 77
TABLE 61 CANADA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 77
TABLE 62 CANADA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 77
TABLE 63 CANADA: EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (USD MILLION) 78
TABLE 64 CANADA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 78
TABLE 65 CANADA: EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 78
TABLE 66 CANADA: EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 79
TABLE 67 CANADA: EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 79
TABLE 68 CANADA: EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 79
TABLE 69 EUROPE EPILEPSY MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 81
TABLE 70 EUROPE EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 81
TABLE 71 EUROPE EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 82
TABLE 72 EUROPE EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 82
TABLE 73 EUROPE EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 82
TABLE 74 EUROPE EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 83
TABLE 75 EUROPE EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 83
TABLE 76 EUROPE EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 83
TABLE 77 EUROPE EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 84
TABLE 78 EUROPE EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 84
TABLE 79 GERMANY EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 84
TABLE 80 GERMANY EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 85
TABLE 81 GERMANY EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 85
TABLE 82 GERMANY EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 85
TABLE 83 GERMANY EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 86
TABLE 84 GERMANY EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 86
TABLE 85 GERMANY EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 86
TABLE 86 GERMANY EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 87
TABLE 87 GERMANY EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 87
TABLE 88 FRANCE EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 87
TABLE 89 FRANCE EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 88
TABLE 90 FRANCE EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 88
TABLE 91 FRANCE EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 88
TABLE 92 FRANCE EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 89
TABLE 93 FRANCE EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 89
TABLE 94 FRANCE EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 89
TABLE 95 FRANCE EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 90
TABLE 96 FRANCE EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 90
TABLE 97 UK EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 90
TABLE 98 UK EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 91
TABLE 99 UK EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 91
TABLE 100 UK EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 91
TABLE 101 UK EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 92
TABLE 102 UK EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 92
TABLE 103 UK EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 92
TABLE 104 UK EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 93
TABLE 105 UK EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 93
TABLE 106 ITALY EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 93
TABLE 107 ITALY EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 94
TABLE 108 ITALY EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 94
TABLE 109 ITALY EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 94
TABLE 110 ITALY EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 95
TABLE 111 ITALY EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 95
TABLE 112 ITALY EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 95
TABLE 113 ITALY EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 96
TABLE 114 ITALY EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 96
TABLE 115 SPAIN EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 96
TABLE 116 SPAIN EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 97
TABLE 117 SPAIN EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 97
TABLE 118 SPAIN EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 97
TABLE 119 SPAIN EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 98
TABLE 120 SPAIN EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 98
TABLE 121 SPAIN EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 98
TABLE 122 SPAIN EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 99
TABLE 123 SPAIN EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 99
TABLE 124 REST OF EUROPE EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 99
TABLE 125 REST OF EUROPE EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 100
TABLE 126 REST OF EUROPE EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 100
TABLE 127 REST OF EUROPE EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 100
TABLE 128 REST OF EUROPE EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 101
TABLE 129 REST OF EUROPE EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 101
TABLE 130 REST OF EUROPE EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 101
TABLE 131 REST OF EUROPE EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 102
TABLE 132 REST OF EUROPE EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 102
TABLE 133 PUBLIC PLAYERS STOCK SUMMARY 106
TABLE 134 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 106
TABLE 135 PRODUCT LAUNCH/ PRODUCT APPROVAL 107
TABLE 136 ACQUISITION 107
TABLE 137 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED 109
TABLE 138 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 112
TABLE 139 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENTS 113
TABLE 140 ABBOTT: PRODUCTS OFFERED 116
TABLE 141 CIPLA LTD: PRODUCTS OFFERED 119
TABLE 142 UCB S.A: PRODUCT OFFERED 122
TABLE 143 UCB S.A: KEY DEVELOPMENTS 123
TABLE 144 H. LUNDBECK A/S: PRODUCT OFFERED 125
TABLE 145 EISAI CO., LTD: PRODUCT OFFERED 128
TABLE 146 NOVARTIS AG: PRODUCTS OFFERED 131
TABLE 147 GLAXOSMITHKLINE PLC: PRODCUTS OFFERED 134
TABLE 148 SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCTS OFFERED 137
LIST OF FIGURES
FIGURE 1 NORTH AMERICA AND EUROPE EPILEPSY MARKET: STRUCTURE 20
FIGURE 2 NORTH AMERICA AND EUROPE EPILEPSY MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032) 37
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 39
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032) 40
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: NORTH AMERICA AND EUROPE EPILEPSY MARKET 42
FIGURE 6 NORTH AMERICA AND EUROPE EPILEPSY MARKET, CONDITION SEGMENT ATTRACTIVENESS, 2022-2032 (USD MILLION) 50
FIGURE 7 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY CONDITION, 2022 & 2032 (USD MILLION) 51
FIGURE 8 NORTH AMERICA AND EUROPE EPILEPSY MARKET SHARE (%), BY CONDITION, 2022 52
FIGURE 9 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2022 & 2032 (USD MILLION) 54
FIGURE 10 NORTH AMERICA AND EUROPE EPILEPSY MARKET SHARE (%), BY DIAGNOSIS & TREATMENT, 2022 55
FIGURE 11 NORTH AMERICA AND EUROPE EPILEPSY MARKET, END USER SEGMENT ATTRACTIVENESS, 2022-2032 (USD MILLION) 65
FIGURE 12 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY END USER, 2022 & 2032 (USD MILLION) 66
FIGURE 13 NORTH AMERICA AND EUROPE EPILEPSY MARKET SHARE (%), BY END USER, 2022 67
FIGURE 14 NORTH AMERICA MARKET ANALYSIS: EPILEPSY MARKET, 2019-2032 (USD MILLION) 69
FIGURE 15 NORTH AMERICA: EPILEPSY MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION) 70
FIGURE 16 NORTH AMERICA: EPILEPSY MARKET SHARE (%), BY COUNTRY, 2022 70
FIGURE 17 EUROPE MARKET ANALYSIS: EPILEPSY MARKET, 2019-2032 (USD MILLION) 80
FIGURE 18 EUROPE EPILEPSY MARKET SHARE, BY COUNTRY, 2022 (% SHARE) 80
FIGURE 19 EUROPE EPILEPSY MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION) 81
FIGURE 20 EPILEPSY MARKET PLAYERS: COMPETITIVE ANALSIS, 2022 104
FIGURE 21 COMPETITOR DASHBOARD: NORTH AMERICA & EUROPE EPILEPSY MARKET 105
FIGURE 22 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT 109
FIGURE 23 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS 110
FIGURE 24 BOSTON SCIENTIFIC CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 112
FIGURE 25 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS 113
FIGURE 26 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT 116
FIGURE 27 ABBOTT: SWOT ANALYSIS 117
FIGURE 28 CIPLA LTD: FINANCIAL OVERVIEW 119
FIGURE 29 CIPLA LTD: SWOT ANALYSIS 120
FIGURE 30 UCB S.A: FINANCIAL OVERVIEW SNAPSHOT 122
FIGURE 31 H. LUNDBECK A/S: FINANCIAL OVERVIEW SNAPSHOT 125
FIGURE 32 EISAI CO., LTD: FINANCIAL OVERVIEW SNAPSHOT 128
FIGURE 33 NOVARTIS AG: FINANCIAL OVERVIEW 131
FIGURE 34 NOVARTIS AG: SWOT ANALYSIS 132
FIGURE 35 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW 134
FIGURE 36 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW 137
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們